drugset / Trial / NCT05215847
Study to Evaluate ARD-101 in Adults Receiving Bariatric Surgery
Phase 2
Completed
12 enrolled
Aardvark Therapeutics, Inc.
University of California, San Diego · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate safety and efficacy of twice-daily ARD-101 in subjects at least one year after bariatric surgery (sleeve gastrectomy or gastric bypass).
Timeline
- Start
- 2022-03-01
- Primary completion
- 2023-02-03
- Completion
- 2023-02-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ARD-101 | Small molecule | 200 mg | Oral |